|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
FI903489A0
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP0604580A1
(en)
|
1991-09-19 |
1994-07-06 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
DK0616640T3
(da)
|
1991-12-02 |
2004-12-20 |
Medical Res Council |
Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
|
US7138500B1
(en)
|
1993-05-07 |
2006-11-21 |
Immunex Corporation |
Antibodies to human 4-1BB
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
DE69624436T2
(de)
*
|
1995-04-08 |
2003-08-28 |
Lg Chemical Ltd., Seoul/Soul |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
|
US5994619A
(en)
|
1996-04-01 |
1999-11-30 |
University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus |
Production of chimeric bovine or porcine animals using cultured inner cell mass cells
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド |
免疫療法のctla−4結合ペプチド
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
DK2112166T3
(en)
|
1998-12-23 |
2019-02-04 |
Pfizer |
Human monoclonal antibodies to CTLA-4
|
|
US6974684B2
(en)
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
|
US20030118588A1
(en)
|
1999-05-22 |
2003-06-26 |
Linda Diehl |
Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
DE60022369T2
(de)
|
1999-10-04 |
2006-05-18 |
Medicago Inc., Sainte Foy |
Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
|
|
JP4200627B2
(ja)
|
2000-03-01 |
2008-12-24 |
味の素株式会社 |
変異型チロシンリプレッサー遺伝子とその利用
|
|
EP2796468A2
(en)
|
2001-01-05 |
2014-10-29 |
Pfizer Inc |
Antibodies to insulin-like growth factor I receptor
|
|
CA2436326C
(en)
|
2001-01-09 |
2012-08-14 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
|
|
CA2447851C
(en)
|
2001-06-28 |
2012-08-28 |
Domantis Limited |
Dual-specific ligand and its use
|
|
CN1604795B
(zh)
|
2001-08-17 |
2010-05-26 |
科勒制药股份公司 |
具有提高的活性的组合基序免疫刺激寡肽
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
AU2003217906A1
(en)
|
2002-03-01 |
2003-09-16 |
Dyax Corp. |
Modular recombinatorial display libraries
|
|
EP1517921B1
(en)
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
WO2004010947A2
(en)
*
|
2002-07-30 |
2004-02-05 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
PL216630B1
(pl)
|
2002-10-17 |
2014-04-30 |
Genmab As |
Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
EP1578801A2
(en)
|
2002-12-27 |
2005-09-28 |
Domantis Limited |
Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
|
|
JP4889493B2
(ja)
|
2003-05-14 |
2012-03-07 |
ドマンティス リミテッド |
ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
|
|
SI1639011T1
(sl)
|
2003-06-30 |
2009-04-30 |
Domantis Ltd |
Pegilirana protitelesa z enojno domeno (dAb)
|
|
AR046094A1
(es)
*
|
2003-10-10 |
2005-11-23 |
Bristol Myers Squibb Co |
Anticuerpos completamente humanos contra 4-1bb humano
|
|
US7288638B2
(en)
*
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
ES2672640T3
(es)
|
2003-11-05 |
2018-06-15 |
Roche Glycart Ag |
Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
US20070253961A1
(en)
|
2004-06-09 |
2007-11-01 |
Ulsan Industrial Education Foundation |
Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
|
|
US20080152655A1
(en)
|
2004-09-08 |
2008-06-26 |
The Ohio State University Research Foundation |
Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
|
|
WO2006055697A2
(en)
|
2004-11-17 |
2006-05-26 |
Board Of Regents, The University Of Texas System |
Cancer immunotherapy incorporating p53
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
AU2005325801A1
(en)
|
2005-01-31 |
2006-08-03 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
EP2399935A3
(en)
|
2005-02-15 |
2012-02-22 |
GTC Biotherapeutics, Inc. |
An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
JP2008542354A
(ja)
|
2005-06-03 |
2008-11-27 |
ファイザー・プロダクツ・インク |
癌治療におけるerbB2阻害剤と他の治療薬の併用
|
|
TWI478940B
(zh)
|
2005-08-26 |
2015-04-01 |
Roche Glycart Ag |
具有經改變細胞傳訊活性之改質抗原結合分子
|
|
CN1294146C
(zh)
|
2005-10-17 |
2007-01-10 |
山东大学 |
与t细胞表面共刺激分子cd137结合的多肽及其应用
|
|
AU2015201981A1
(en)
*
|
2005-10-21 |
2015-05-07 |
Genzyme Corporation |
Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
|
|
WO2007062093A2
(en)
|
2005-11-22 |
2007-05-31 |
Incyte Corporation |
Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
|
|
AU2006317242A1
(en)
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
CL2007003291A1
(es)
*
|
2006-11-15 |
2008-07-04 |
Medarex Inc |
Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-cd137 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
US7879984B2
(en)
|
2007-07-31 |
2011-02-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human CD20 and method of using thereof
|
|
WO2009022215A1
(en)
|
2007-08-13 |
2009-02-19 |
Pfizer Inc. |
Combination motif immune stimulatory oligonucleotides with improved activity
|
|
CA3128656A1
(en)
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
|
AU2013202755B2
(en)
|
2007-08-22 |
2016-05-12 |
Cytomx Therapeutics, Inc. |
Activatable binding polypeptides and methods of identification and use thereof
|
|
ES2336873B1
(es)
|
2007-11-07 |
2011-01-24 |
Proyecto De Biomedicina Cima, S.L. |
Composicion farmaceutica para el tratamiento de cancer.
|
|
HUE032735T2
(en)
|
2007-12-14 |
2017-10-30 |
Bristol Myers Squibb Co |
Binding molecules for the human OX40 receptor
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US20120076722A1
(en)
|
2009-05-14 |
2012-03-29 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
US9193791B2
(en)
|
2010-08-03 |
2015-11-24 |
City Of Hope |
Development of masked therapeutic antibodies to limit off-target effects
|
|
CN103221428B
(zh)
|
2010-09-09 |
2016-02-10 |
辉瑞公司 |
4-1bb结合分子
|
|
HRP20210642T1
(hr)
|
2010-11-12 |
2021-05-28 |
Nektar Therapeutics |
Konjugati il-2 ostatka i polimera
|
|
WO2013192550A2
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
CN105247050B
(zh)
|
2013-03-14 |
2020-06-16 |
天演药业 |
用于文库构建、亲和力结合剂筛选和其表达的整合系统
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
RU2715232C2
(ru)
|
2013-09-25 |
2020-02-26 |
Сайтомкс Терапьютикс, Инк. |
Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
SG11201604965RA
(en)
|
2013-12-20 |
2016-07-28 |
Univ Singapore |
Differentiation therapy with cd137 ligand agonists
|
|
US10010587B2
(en)
|
2014-02-21 |
2018-07-03 |
Nektar Therapeutics |
IL-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody
|
|
JP2017513818A
(ja)
*
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
ES2900898T3
(es)
|
2014-04-07 |
2022-03-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecíficos inmunoactivadores
|
|
AU2015292406B2
(en)
|
2014-07-25 |
2021-03-11 |
Cytomx Therapeutics, Inc |
Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
WO2016115275A1
(en)
|
2015-01-13 |
2016-07-21 |
City Of Hope |
Ctla4-binding protein peptide-linker masks
|
|
CA2976446A1
(en)
|
2015-02-13 |
2016-08-18 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
TW201632559A
(zh)
|
2015-02-22 |
2016-09-16 |
索倫多醫療公司 |
結合cd137之抗體治療劑
|
|
AU2016233495B2
(en)
|
2015-03-13 |
2022-02-24 |
Cytomx Therapeutics, Inc |
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
|
|
SG10202110908WA
(en)
|
2015-05-04 |
2021-11-29 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
US11008396B2
(en)
|
2015-05-21 |
2021-05-18 |
Alligator Bioscience Ab |
Polypeptides
|
|
WO2016200645A1
(en)
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
CN114591433A
(zh)
|
2015-07-13 |
2022-06-07 |
西托姆克斯治疗公司 |
抗pd-1抗体、可活化抗pd-1抗体及其使用方法
|
|
JP6845846B6
(ja)
*
|
2015-09-22 |
2021-04-21 |
ディンフー バイオターゲット カンパニー リミテッド |
抗ヒトcd137の完全ヒト抗体及びその用途
|
|
GB201519481D0
(en)
|
2015-11-04 |
2015-12-16 |
Cancer Rec Tech Ltd |
Immunomodulatory antibodies
|
|
US10618960B2
(en)
|
2015-12-15 |
2020-04-14 |
Oncoimmune, Inc. |
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
US20190016812A1
(en)
|
2015-12-22 |
2019-01-17 |
Abbvie Stemcentrx Llc |
Novel anti-tnfsf9 antibodies and methods of use
|
|
EP3417293A1
(en)
|
2016-02-18 |
2018-12-26 |
Institut Gustave Roussy |
Methods and kits for predicting the sensitivity of a subject to immunotherapy
|
|
KR20180132070A
(ko)
|
2016-03-03 |
2018-12-11 |
큐 바이오파마, 인크. |
T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
|
|
SG10201603721TA
(en)
|
2016-05-10 |
2017-12-28 |
Agency Science Tech & Res |
Anti-CTLA-4 Antibodies
|
|
EP3464362B1
(en)
|
2016-05-27 |
2020-12-09 |
AbbVie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
|
CA3030636A1
(en)
*
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
CN107840887B
(zh)
|
2016-09-21 |
2022-03-25 |
基石药业(苏州)有限公司 |
一种新的pd-1单克隆抗体
|
|
GB201619648D0
(en)
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
WO2018127787A1
(en)
*
|
2017-01-06 |
2018-07-12 |
Eutilex Co., Ltd. |
Anti-human 4-1 bb antibodies and use thereof
|
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
KR20180119135A
(ko)
|
2017-04-24 |
2018-11-01 |
주식회사 제넥신 |
4-1bbl 변이체 및 이를 포함하는 융합 단백질
|
|
CN110709421A
(zh)
|
2017-05-02 |
2020-01-17 |
鳄鱼生物科学公司 |
针对ox40和ctla-4的双特异性抗体
|
|
JP7173993B2
(ja)
|
2017-05-19 |
2022-11-17 |
ウーシー バイオロジクス(シャンハイ)カンパニー リミテッド |
細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対する新規モノクローナル抗体
|
|
BR112020000719A2
(pt)
|
2017-07-11 |
2020-07-14 |
Compass Therapeutics Llc |
anticorpos agonistas que ligam o cd137 humano e seus usos
|
|
GB201712032D0
(en)
|
2017-07-26 |
2017-09-06 |
Bioinvent Int Ab |
Antibodies and uses thereof
|
|
CN111511762B
(zh)
*
|
2017-08-21 |
2025-05-06 |
天演药业公司 |
抗cd137分子及其用途
|
|
CA3072143A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Dynamic human heavy chain antibody libraries
|
|
JP7324744B2
(ja)
|
2017-08-21 |
2023-08-10 |
アダジーン インコーポレイテッド |
ダイナミックヒト抗体軽鎖ライブラリー
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
WO2019104716A1
(en)
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
AU2020287181A1
(en)
|
2019-06-05 |
2022-01-20 |
Adagene Pte. Ltd. |
Anti-CD137L antibodies and methods of using same
|
|
CA3177717A1
(en)
|
2020-05-13 |
2021-11-18 |
Adagene Ag |
Compositions and methods for treating cancer
|
|
CA3181677A1
(en)
|
2020-06-23 |
2021-12-30 |
Guizhong Liu |
Combination therapy comprising anti-cd137 antibodies
|
|
WO2022170619A1
(en)
|
2021-02-11 |
2022-08-18 |
Adagene Pte. Ltd. |
Anti-cd3 antibodies and methods of use thereof
|
|
WO2023168547A1
(en)
|
2022-03-07 |
2023-09-14 |
Adagene Pte. Ltd. |
Anti-cd137 antibodies and methods of making and using the same
|